Home / News / 2017 / JSR has exclusively licensed intellectual property on microbiome effective to cancer immunotherapies

News

JSR has exclusively licensed intellectual property on microbiome effective to cancer immunotherapies

CORPORATE  10/30/2017
Tokyo, Japan – October 27, 2017 – JSR Corporation (Representative Director and President: Mitsunobu Koshiba, hereinafter referred to as ”JSR”) has been exclusively licensed intellectual property from Keio University and The University of Tokyo on microbiome effective to cancer immunotherapies and infectious diseases. Also, JSR granted exclusive licenses of key intellectual property to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics to Vedanta Biosciences Inc. (CEO: Bernat Olle, hereafter referred to as “Vedanta”), a pioneering company developing a new category of therapies for immune and infectious diseases based on rationally designed consortia of human microbiome-derived bacteria.

A team at Keio University (Prof. Kenya Honda) and collaborators at The University of Tokyo found that these microbiomes activate CD8+ T cells, a type of white blood cell that is the predominant effector in cancer immunotherapy, to remove cancerous and virus infected cells and it is expected to increase effectiveness of therapies for cancer and infectious diseases. JSR will identify microbiome-derived physiological active substances and develop in vitro diagnostic products using those substances through activity of JSR-Keio University Medical and Chemical Innovation Center (JKiC). Vedanta will develop and advance cancer immunotherapy.

About JSR Corporation
From synthetic rubbers for tires to semiconductor materials, display materials and, life sciences business, materials created by JSR play a role in almost every aspect of daily life. JSR has continuously expanded its business fields by leveraging its proprietary polymer technologies. JSR-Keio University Medical and Chemical Innovation Center (JKiC), a joint research facility, is open in October 2017 to create innovation through investigating the wholly novel concept of fusing medicine and chemistry, which will lead to establish practical technologies that contribute to global society with people living long and healthy lives.

About Key Intellectual Properties
Keio University and The University of Tokyo joined Leading Advanced Projects for medical innovation (“LEAP”) in Advanced Research and Development Programs for Medical Innovation at Japan Agency for Medical Research and Development (“AMED”) in 2016, whose Research and Development Subject entitled " Development of therapeutic cocktails of bacteria isolated from the gut microbiota" (“AMED-LEAP Research Program”); The key intellectual properties were bore as a part of AMED-LEAP Research Program.

About Vedanta Biosciences
Vedanta Biosciences is pioneering development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, with clinical trials expected to begin in the second half of 2017. An affiliate of PureTech Health (PureTech Health plc, PRTC.L).